<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8918">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00792688</url>
  </required_header>
  <id_info>
    <org_study_id>GLYC-101-1b</org_study_id>
    <nct_id>NCT00792688</nct_id>
  </id_info>
  <brief_title>Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation</brief_title>
  <official_title>Double-Blind, Randomized, Placebo-Controlled Phase 2 Study to Investigate the Safety and Efficacy of 0.1% and 1.0% Topically Applied GLYC-101, Compared to Placebo, in Patients Undergoing Carbon Dioxide Laser Skin Resurfacing of the Lower Eyelids.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glycotex, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glycotex, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate safety and efficacy of topically
      applied Glucoprime gel (GLYC-101, 0.1% and GLYC-101, 1.0%) in promoting wound healing in
      cosmetic surgery patients undergoing Carbon Dioxide Laser Skin Resurfacing (CO2 LSR) of the
      lower eyelids. The study will observe the effects of the topical agent over the course of 1
      month following the initial treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to Complete Wound Closure (Epithelialization)</measure>
    <time_frame>Over the course of 1 month following the initial treatment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects were evaluated daily from the time of the laser procedure and initial application of test article until the subject's wounds reached 100% epithelialization. Efficacy was assessed based on the time to complete epithelialization in terms of the number of days from Day 1 (day of laser ablation) to the day on which complete epithelialization was observed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cosmesis/11-point Likert Scale</measure>
    <time_frame>At 1 month following the initial treatment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The cosmetic effect on each lower eyelid using an 11-point Likert Scale (0 = not healed and 10 = healed).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Wounds</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLYC-101 Gel, 0.1% on one eyelid and Placebo Gel on the other eyelid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLYC-101 Gel, 1.0% on one eyelid and Placebo Gel on the other eyelid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLYC-101 Gel, 0.1% on one eyelid and GLYC-101 Gel, 1.0% on the other eyelid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLYC-101 Gel (0.1%)</intervention_name>
    <description>Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLYC-101 Gel (1.0%)</intervention_name>
    <description>Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLYC-101 Placebo</intervention_name>
    <description>Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female healthy volunteer subjects, between 25 and 70 years of age, giving
             informed consent for facial laser ablation of the lower eyelid areas for the purpose
             of wrinkle removal.

          -  Lower eyelid skin is free of any irritation, scarring or dermatologic conditions
             which might interfere with the study.

          -  Willing and able to participate in the study and follow all study directions.

          -  Able to read, understand and sign the consent form prior to any study related
             procedures.

        Exclusion Criteria:

          -  Female subjects who are pregnant, nursing, or planning a pregnancy during the course
             of the study, as determined by the interview and a urine pregnancy test.

          -  Presence of irritation or dermatologic skin conditions in the lower eyelid area.

          -  Known allergies to materials within the test formulations (i.e., yeast and/or yeast
             products).

          -  Use of topical or systemic drugs (corticosteroids, retinoids, immune modulators,
             immune suppressants, drugs with potential for contact dermatitis, drugs with
             potential for skin discoloration) that may have an effect on wound healing or may
             impact skin pigmentation.

          -  A history, upon wounding, of developing thickened scars, keloids, or excessive
             pigment change.

          -  An unstable or severe inter-current medical condition that, in the opinion of the
             investigator, might interfere with interpretation of study results or render the
             subject at high risk for treatment complications.

          -  Use of any investigational medication or device for any indication within 30 days of
             screening.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Joseph, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Clinical Testing Center of Beverly Hills</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CLINICAL TESTING CENTER of BEVERLY HILLS</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <lastchanged_date>July 22, 2011</lastchanged_date>
  <firstreceived_date>November 14, 2008</firstreceived_date>
  <firstreceived_results_date>June 23, 2011</firstreceived_results_date>
  <responsible_party>
    <name_title>John H. Joseph, MD/ Principal Investigator</name_title>
    <organization>The Clinical Testing Center of Beverly Hills</organization>
  </responsible_party>
  <keyword>burn wounds</keyword>
  <keyword>wound healing</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment started in October 2008 and ended in 2009 at a single site, Clinical Testing Center of Beverly Hills, Beverly Hills, California, United States, 90210.</recruitment_details>
      <pre_assignment_details>All subjects needed to meet specific inclusion and exclusion criteria as described in the Eligibility Criteria section. Eligible subjects were randomly assigned to receive GLYC-101 0.1%, GLYC-101 1%, or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GLYC-101 Gel, 0.1% on One Eyelid &amp; Placebo on the Other Eyelid</title>
          <description>GLYC-101 Gel (0.1%) Topical administration to the laser-ablated area on Days 1 (day of laser ablation), 2, 3, 4, and 5.
Placebo Gel Topical administration to the laser-ablated area on Days 1 (day of laser ablation), 2, 3, 4, and 5.</description>
        </group>
        <group group_id="P2">
          <title>GLYC-101 Gel, 1.0% on One Eyelid &amp; Placebo on the Other Eyelid</title>
          <description>GLYC-101 Gel (1%) Topical administration to the laser-ablated area on Days 1 (day of laser ablation), 2, 3, 4, and 5.
Placebo Gel Topical administration to the laser-ablated area on Days 1 (day of laser ablation), 2, 3, 4, and 5.</description>
        </group>
        <group group_id="P3">
          <title>GLYC-101 Gel 0.1% on 1 Eyelid &amp; GLYC-101 Gel 1.0% on the Other</title>
          <description>GLYC-101 Gel (0.1%) Topical administration to the laser-ablated area on Days 1 (day of laser ablation), 2, 3, 4, and 5.
GLYC-101 Gel (1%) Topical administration to the laser-ablated area on Days 1 (day of laser ablation), 2, 3, 4, and 5.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GLYC-101 Gel, 0.1% on One Eyelid &amp; Placebo on the Other Eyelid</title>
          <description>GLYC-101 Gel (0.1%) Topical administration to the laser-ablated area on Days 1 (day of laser ablation), 2, 3, 4, and 5.
Placebo Gel Topical administration to the laser-ablated area on Days 1 (day of laser ablation), 2, 3, 4, and 5.</description>
        </group>
        <group group_id="B2">
          <title>GLYC-101 Gel, 1.0% on One Eyelid &amp; Placebo on the Other Eyelid</title>
          <description>GLYC-101 Gel (1%) Topical administration to the laser-ablated area on Days 1 (day of laser ablation), 2, 3, 4, and 5.
Placebo Gel Topical administration to the laser-ablated area on Days 1 (day of laser ablation), 2, 3, 4, and 5.</description>
        </group>
        <group group_id="B3">
          <title>GLYC-101 Gel 0.1% on 1 Eyelid &amp; GLYC-101 Gel 1.0% on the Other</title>
          <description>GLYC-101 Gel (0.1%) Topical administration to the laser-ablated area on Days 1 (day of laser ablation), 2, 3, 4, and 5.
GLYC-101 Gel (1%) Topical administration to the laser-ablated area on Days 1 (day of laser ablation), 2, 3, 4, and 5.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="9"/>
                <measurement group_id="B4" value="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="8"/>
                <measurement group_id="B4" value="24"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="53.1" spread="7.98"/>
                <measurement group_id="B2" value="46.4" spread="12.83"/>
                <measurement group_id="B3" value="53.3" spread="9.41"/>
                <measurement group_id="B4" value="51.1" spread="10.25"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="22"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="9"/>
                <measurement group_id="B4" value="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Complete Wound Closure (Epithelialization)</title>
        <description>Subjects were evaluated daily from the time of the laser procedure and initial application of test article until the subject’s wounds reached 100% epithelialization. Efficacy was assessed based on the time to complete epithelialization in terms of the number of days from Day 1 (day of laser ablation) to the day on which complete epithelialization was observed.</description>
        <time_frame>Over the course of 1 month following the initial treatment.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was Per Protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>All Treatments GLYC-101 Gel, 0.1%</title>
          </group>
          <group group_id="O2">
            <title>All Treatments GLYC-101 Gel, 1.0%</title>
          </group>
          <group group_id="O3">
            <title>All Treatments Placebo</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Complete Wound Closure (Epithelialization)</title>
            <description>Subjects were evaluated daily from the time of the laser procedure and initial application of test article until the subject’s wounds reached 100% epithelialization. Efficacy was assessed based on the time to complete epithelialization in terms of the number of days from Day 1 (day of laser ablation) to the day on which complete epithelialization was observed.</description>
            <units>days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10.9" spread="5.17"/>
                  <measurement group_id="O2" value="13.1" spread="8.31"/>
                  <measurement group_id="O3" value="16.3" spread="9.93"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0062</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0331</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cosmesis/11-point Likert Scale</title>
        <description>The cosmetic effect on each lower eyelid using an 11-point Likert Scale (0 = not healed and 10 = healed).</description>
        <time_frame>At 1 month following the initial treatment.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>All Treatments GLYC-101 Gel, 0.1%</title>
          </group>
          <group group_id="O2">
            <title>All Treatments GLYC-101 Gel, 1.0%</title>
          </group>
          <group group_id="O3">
            <title>All Treatments Placebo</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cosmesis/11-point Likert Scale</title>
            <description>The cosmetic effect on each lower eyelid using an 11-point Likert Scale (0 = not healed and 10 = healed).</description>
            <units>scores on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8.9" spread="1.28"/>
                  <measurement group_id="O2" value="8.6" spread="1.17"/>
                  <measurement group_id="O3" value="8.5" spread="1.50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) were collected over the course of 1 month.</time_frame>
      <desc>AEs were collected at baseline and each study visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>GLYC-101 Gel, 0.1% on One Eyelid &amp; Placebo on the Other Eyelid</title>
          <description>GLYC-101 Gel (0.1%) Topical administration to the laser-ablated area on Days 1 (day of laser ablation), 2, 3, 4, and 5.
Placebo Gel Topical administration to the laser-ablated area on Days 1 (day of laser ablation), 2, 3, 4, and 5.</description>
        </group>
        <group group_id="E2">
          <title>GLYC-101 Gel, 1.0% on One Eyelid &amp; Placebo on the Other Eyelid</title>
          <description>GLYC-101 Gel (1%) Topical administration to the laser-ablated area on Days 1 (day of laser ablation), 2, 3, 4, and 5.
Placebo Gel Topical administration to the laser-ablated area on Days 1 (day of laser ablation), 2, 3, 4, and 5.</description>
        </group>
        <group group_id="E3">
          <title>GLYC-101 Gel 0.1% on 1 Eyelid &amp; GLYC-101 Gel 1.0% on the Other</title>
          <description>GLYC-101 Gel (0.1%) Topical administration to the laser-ablated area on Days 1 (day of laser ablation), 2, 3, 4, and 5.
GLYC-101 Gel (1%) Topical administration to the laser-ablated area on Days 1 (day of laser ablation), 2, 3, 4, and 5.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>HIV test positive</sub_title>
                <description>This Serious Adverse Event is not related to study drugs.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" events="10" subjects_affected="6" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" events="70" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E2" events="62" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" events="71" subjects_affected="9" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E2" events="14" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E3" events="13" subjects_affected="6" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Chemical eye injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of up to 90 days. The sponsor can require changes to the communication to remove any confidential information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Reinhard Koenig, CEO</name_or_title>
      <organization>Glycotex, Inc.</organization>
      <phone>301-670-2825</phone>
      <email>Reinhard.Koenig@glycotexinc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
